172 related articles for article (PubMed ID: 20859151)
1. Endometrial safety of ultra-low-dose estradiol vaginal tablets.
Simon J; Nachtigall L; Ulrich LG; Eugster-Hausmann M; Gut R
Obstet Gynecol; 2010 Oct; 116(4):876-883. PubMed ID: 20859151
[TBL] [Abstract][Full Text] [Related]
2. Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy.
Ulrich LS; Naessen T; Elia D; Goldstein JA; Eugster-Hausmann M;
Climacteric; 2010 Jun; 13(3):228-37. PubMed ID: 20423243
[TBL] [Abstract][Full Text] [Related]
3. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet.
Simon J; Nachtigall L; Gut R; Lang E; Archer DF; Utian W
Obstet Gynecol; 2008 Nov; 112(5):1053-60. PubMed ID: 18978105
[TBL] [Abstract][Full Text] [Related]
4. Use of oral estradiol plus vaginal progesterone in healthy postmenopausal women.
Sriprasert I; Mert M; Mack WJ; Hodis HN; Shoupe D
Maturitas; 2021 Dec; 154():13-19. PubMed ID: 34736575
[TBL] [Abstract][Full Text] [Related]
5. Local oestrogen for vaginal atrophy in postmenopausal women.
Suckling J; Lethaby A; Kennedy R
Cochrane Database Syst Rev; 2003; (4):CD001500. PubMed ID: 14583935
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial.
Bachmann G; Lobo RA; Gut R; Nachtigall L; Notelovitz M
Obstet Gynecol; 2008 Jan; 111(1):67-76. PubMed ID: 18165394
[TBL] [Abstract][Full Text] [Related]
7. 17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis.
Rioux JE; Devlin MC; Gelfand MM; Steinberg WM; Hepburn DS
Menopause; 2018 Nov; 25(11):1208-1213. PubMed ID: 30358715
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
[TBL] [Abstract][Full Text] [Related]
9. Local oestrogen for vaginal atrophy in postmenopausal women.
Suckling J; Lethaby A; Kennedy R
Cochrane Database Syst Rev; 2006 Oct; (4):CD001500. PubMed ID: 17054136
[TBL] [Abstract][Full Text] [Related]
10. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Melisko ME; Goldman ME; Hwang J; De Luca A; Fang S; Esserman LJ; Chien AJ; Park JW; Rugo HS
JAMA Oncol; 2017 Mar; 3(3):313-319. PubMed ID: 27832260
[TBL] [Abstract][Full Text] [Related]
11. Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: a randomized, placebo-controlled study.
Fernandes T; Pedro AO; Baccaro LF; Costa-Paiva LH
Menopause; 2018 Jun; 25(6):641-647. PubMed ID: 29462095
[TBL] [Abstract][Full Text] [Related]
12. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis.
Rioux JE; Devlin C; Gelfand MM; Steinberg WM; Hepburn DS
Menopause; 2000; 7(3):156-61. PubMed ID: 10810960
[TBL] [Abstract][Full Text] [Related]
13. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
[TBL] [Abstract][Full Text] [Related]
14. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women.
Genazzani AR; Schmelter T; Schaefers M; Gerlinger C; Gude K
Climacteric; 2013 Aug; 16(4):490-8. PubMed ID: 23531117
[TBL] [Abstract][Full Text] [Related]
15. Endometrial safety of ospemifene: results of the phase 2/3 clinical development program.
Constantine GD; Goldstein SR; Archer DF
Menopause; 2015 Jan; 22(1):36-43. PubMed ID: 24977459
[TBL] [Abstract][Full Text] [Related]
16. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus.
Simon JA; Lin VH; Radovich C; Bachmann GA;
Menopause; 2013 Apr; 20(4):418-27. PubMed ID: 23096251
[TBL] [Abstract][Full Text] [Related]
17. Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy.
Simon JA; Maamari RV
Climacteric; 2013 Aug; 16 Suppl 1():37-43. PubMed ID: 23848490
[TBL] [Abstract][Full Text] [Related]
18. Endometrial response in estrogen replacement therapy quarterly combined with a progestogen.
Boerrigter PJ; van de Weijer PH; Baak JP; Fox H; Haspels AA; Kenemans P
Maturitas; 1996 May; 24(1-2):63-71. PubMed ID: 8794436
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy.
Ayton RA; Darling GM; Murkies AL; Farrell EA; Weisberg E; Selinus I; Fraser ID
Br J Obstet Gynaecol; 1996 Apr; 103(4):351-8. PubMed ID: 8605133
[TBL] [Abstract][Full Text] [Related]
20. Sexual frequency and pain in a randomized clinical trial of vaginal estradiol tablets, moisturizer, and placebo in postmenopausal women.
Mitchell CM; Guthrie KA; Larson J; Diem S; LaCroix AZ; Caan B; Shifren JL; Woods NF; Heiman JR; Lindau ST; Reed SD
Menopause; 2019 Aug; 26(8):816-822. PubMed ID: 30994576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
